![Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents - ScienceDirect Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0197018611002440-fx1.jpg)
Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents - ScienceDirect
![Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes | CNS Spectrums | Cambridge Core Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary-alt:20171002105054-43413-mediumThumb-S1092852917000608_fig7g.jpg?pub-status=live)
Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes | CNS Spectrums | Cambridge Core
![Frontiers | Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases Frontiers | Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases](https://www.frontiersin.org/files/Articles/222411/fnins-10-00451-HTML/image_m/fnins-10-00451-g001.jpg)
Frontiers | Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
![Current Perspectives on Selective Dopamine D3 Receptor Antagonists/Partial Agonists as Pharmacotherapeutics for Opioid and Psychostimulant Use Disorders | SpringerLink Current Perspectives on Selective Dopamine D3 Receptor Antagonists/Partial Agonists as Pharmacotherapeutics for Opioid and Psychostimulant Use Disorders | SpringerLink](https://media.springernature.com/lw685/springer-static/image/chp%3A10.1007%2F7854_2022_347/MediaObjects/516529_1_En_347_Fig4_HTML.png)
Current Perspectives on Selective Dopamine D3 Receptor Antagonists/Partial Agonists as Pharmacotherapeutics for Opioid and Psychostimulant Use Disorders | SpringerLink
![Frontiers | Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases Frontiers | Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases](https://www.frontiersin.org/files/Articles/222411/fnins-10-00451-HTML/image_m/fnins-10-00451-g011.jpg)
Frontiers | Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
![Figure 4, Known chemical series of selective D2versus D3 DAR antagonist - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf Figure 4, Known chemical series of selective D2versus D3 DAR antagonist - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK169449/bin/ml321f5.jpg)
Figure 4, Known chemical series of selective D2versus D3 DAR antagonist - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf
![Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism | eLife Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism | eLife](https://iiif.elifesciences.org/lax/52189%2Felife-52189-fig3-v2.tif/full/1500,/0/default.jpg)
Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism | eLife
![Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis | Journal of Pharmacology and Experimental Therapeutics Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/379/1/85/F1.large.jpg)
Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis | Journal of Pharmacology and Experimental Therapeutics
![Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists | Journal of Medicinal Chemistry Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm500126s/asset/images/large/jm-2014-00126s_0017.jpeg)
Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists | Journal of Medicinal Chemistry
Antagonist/partial agonist effects at D3 receptors. Theoretically, D3... | Download Scientific Diagram
![MilliporeSigma Calbiochem Dopamine Receptor D3 Antagonist II, YQA14 10mg:Protein | Fisher Scientific MilliporeSigma Calbiochem Dopamine Receptor D3 Antagonist II, YQA14 10mg:Protein | Fisher Scientific](https://assets.fishersci.com/TFS-Assets/CCG/product-images/F585079~p.eps-650.jpg)
MilliporeSigma Calbiochem Dopamine Receptor D3 Antagonist II, YQA14 10mg:Protein | Fisher Scientific
![Biomolecules | Free Full-Text | Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection Biomolecules | Free Full-Text | Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection](https://www.mdpi.com/biomolecules/biomolecules-10-01016/article_deploy/html/images/biomolecules-10-01016-g001.png)